Seino, Y <br/><br/>
Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Aug 2014 
 - 739-47 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12276  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Asian People<br/>Cohort Studies<br/>Diabetes Mellitus, Type 2--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Monitoring<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Follow-Up Studies<br/>Glucagon-Like Peptide-1 Receptor<br/>Humans<br/>Hypoglycemia--prevention & control<br/>Hypoglycemic Agents--administration & dosage<br/>Incretins--administration & dosage<br/>Injections, Subcutaneous<br/>Japan<br/>Male<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Peptides--administration & dosage<br/>Receptors, Glucagon--agonists<br/>Sulfonylurea Compounds--therapeutic use<br/>White People<br/>Young Adult